Phanstiel S. Louise 4
4 · MYRIAD GENETICS INC · Filed Feb 27, 2026
Research Summary
AI-generated summary of this filing
Myriad Genetics Director Phanstiel S. Louise Buys Shares
What Happened
- Director Phanstiel S. Louise acquired a total of 104,507 shares of Myriad Genetics, Inc. (MYGN) in open-market purchases (transaction code P) on Feb 25–27, 2026.
- Feb 25, 2026: 6,100 shares @ $4.74 each — $28,890
- Feb 26, 2026: 50,407 shares @ $4.80 each — $242,105
- Feb 27, 2026: 48,000 shares @ $4.66 each — $223,728
- Total purchased ≈ 104,507 shares for about $494,723. These are purchases (insider buying), not sales or option exercises.
Key Details
- Transaction dates and reported prices: Feb 25–27, 2026; prices shown are weighted averages.
- Footnote F1: Feb 25 purchases were multiple trades at $4.725–$4.75.
- Footnote F2: Feb 26 purchases were multiple trades at $4.71–$5.01.
- Footnote F3: Feb 27 purchases were multiple trades at $4.51–$4.79.
- Shares owned after transaction: not provided in the summary data here — see the full Form 4 for post-transaction holdings.
- Filing timeliness: Form 4 was filed Feb 27, 2026 (period of report begins Feb 25); this appears to be filed within the standard 2-business-day window.
- No option exercises, awards, gifts, or tax-withholding components reported — these were straight open-market purchases.
Context
- Open-market purchases are direct buys of company stock by an insider; they show personal buying activity but do not by themselves prove future performance. For full details and exact per-lot prices, consult the complete Form 4 filing (accession 0001471518-26-000002).
Insider Transaction Report
Form 4
Phanstiel S. Louise
Director
Transactions
- Purchase
Common Stock
[F1]2026-02-25$4.74/sh+6,100$28,890→ 183,544 total - Purchase
Common Stock
[F2]2026-02-26$4.80/sh+50,407$242,105→ 233,951 total - Purchase
Common Stock
[F3]2026-02-27$4.66/sh+48,000$223,728→ 281,951 total
Holdings
- 33,119(indirect: By Trust)
Common Stock
Footnotes (3)
- [F1]The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.725 to $4.75, inclusive. The reporting person undertakes to provide to Myriad Genetics, Inc., any security holder of Myriad Genetics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
- [F2]The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.71 to $5.01, inclusive. The reporting person undertakes to provide to Myriad Genetics, Inc., any security holder of Myriad Genetics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
- [F3]The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.51 to $4.79, inclusive. The reporting person undertakes to provide to Myriad Genetics, Inc., any security holder of Myriad Genetics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
Signature
By: Justin Hunter For: S. Louise Phanstiel|2026-02-27